<DOC>
	<DOCNO>NCT02821754</DOCNO>
	<brief_summary>BACKGROUND : - Various tumor ablative procedure technique show result immunogenic cell death induction peripheral immune response . The term ablative therapy apply trans-arterial catheter chemoembolization ( TACE ) , radiofrequency ablation ( RFA ) cryoablation ( CA ) . - The underlying hypothesis study effect immune checkpoint inhibition enhance TACE , CA RFA patient advance hepatocellular carcinoma ( HCC ) biliary tract carcinoma ( BTC ) . We already demonstrate proof principle well safety feasibility approach anti-CTLA4 therapy . - Based concept PDL1-mediated adaptive resistance emerge role PD1 therapy HCC , would like evaluate combination tremelimumab durvalumab ( ablative therapy ) HCC BTC . Objectives : - To preliminarily evaluate 6-month progression free survival ( PFS ) combine tremelimumab durvalumab patient advance HCC ( either alone cryoablation , TACE RFA ) patient advance biliary tract carcinoma ( BTC ) ( either alone cryoablation RFA ) . ELIGIBILITY : - Histologically cytologically confirm diagnosis HCC biliary tract carcinoma OR histopathological confirmation carcinoma set clinical radiological characteristic , together pathology , highly suggestive diagnosis HCC ( biliary tract carcinoma ) . - Childs-Pugh A/B7 cirrhosis allow . If patient cirrhosis , limitation apply . - Patients must disease amenable potentially curative resection , radiofrequency ablation , liver transplantation . DESIGN : We evaluate combination tremelimumab durvalumab ( ablative therapy ) cohorts A ( HCC ; N=40 ) B ( BTC ; N=30 ) . The first N=10 patient cohort receive tremelimumab durvalumab ( i.e . No interventional radiologic procedure ) . - A : Advanced HCC , BCLC # Stage B/C - N= 1st 10 pt : No ablative procedure Cryoablation/RFA/TACE # # - Tremelimumab 75mg flat dose q28 day 4 dos ; Durvalumab 1500mg flat dose q28 day EOS # # # - 40 total : 10 trem+ dur alone ; 10 trem+ dur + TACE ; 10 trem + dur + RFA ; 10 trem + dur + cryo - B : Intra/extra-hepatic cholangiocarcinoma - N= 1st 10 pt : No ablative procedure ; RFA/ cryoablation - Tremelimumab 75mg flat dose q28 day 4 dos ; Durvalumab 1500mg flat dose q28 day EOS # # # - 30 total : 10 trem+ dur alone ; 10 trem + dur + RFA ; 10 trem - BCLC = Barcelona clinic liver cancer stag system - For BCLC stage B patient TACE may repeat per standard care - EOS = End study treatment meet off-treatment study criterion .</brief_summary>
	<brief_title>A Pilot Study Combined Immune Checkpoint Inhibition Combination With Ablative Therapies Subjects With Hepatocellular Carcinoma ( HCC ) Biliary Tract Carcinomas ( BTC )</brief_title>
	<detailed_description>BACKGROUND : - Various tumor ablative procedure technique show result immunogenic cell death induction peripheral immune response . The term ablative therapy apply trans-arterial catheter chemoembolization ( TACE ) , radiofrequency ablation ( RFA ) cryoablation ( CA ) . - The underlying hypothesis study effect immune checkpoint inhibition enhance TACE , CA RFA patient advance hepatocellular carcinoma ( HCC ) biliary tract carcinoma ( BTC ) . We already demonstrate proof principle well safety feasibility approach anti-CTLA4 therapy . - Based concept PDL1-mediated adaptive resistance emerge role PD1 therapy HCC , would like evaluate combination tremelimumab durvalumab ( ablative therapy ) HCC BTC . Objectives : - To preliminarily evaluate 6-month progression free survival ( PFS ) combine tremelimumab durvalumab patient advance HCC ( either alone cryoablation , TACE RFA ) patient advance biliary tract carcinoma ( BTC ) ( either alone cryoablation RFA ) . ELIGIBILITY : - Histologically cytologically confirm diagnosis HCC biliary tract carcinoma OR histopathological confirmation carcinoma set clinical radiological characteristic , together pathology , highly suggestive diagnosis HCC ( biliary tract carcinoma ) . - Childs-Pugh A/B7 cirrhosis allow . If patient cirrhosis , limitation apply . - Patients must disease amenable potentially curative resection , radiofrequency ablation , liver transplantation . DESIGN : We evaluate combination tremelimumab durvalumab ( ablative therapy ) cohorts A ( HCC ; N=40 ) B ( BTC ; N=30 ) . The first N=10 patient cohort receive tremelimumab durvalumab ( i.e . No interventional radiologic procedure ) . - A : Advanced HCC , BCLC # Stage B/C - N= 1st 10 pt : No ablative procedure Cryoablation/RFA/TACE # # - Tremelimumab 75mg flat dose q28 day 4 dos ; Durvalumab 1500mg flat dose q28 day EOS # # # - 40 total : 10 trem+ dur alone ; 10 trem+ dur + TACE ; 10 trem + dur + RFA ; 10 trem + dur + cryo - B : Intra/extra-hepatic cholangiocarcinoma - N= 1st 10 pt : No ablative procedure ; RFA/ cryoablation - Tremelimumab 75mg flat dose q28 day 4 dos ; Durvalumab 1500mg flat dose q28 day EOS # # # - 30 total : 10 trem+ dur alone ; 10 trem + dur + RFA ; 10 trem - BCLC = Barcelona clinic liver cancer stag system - For BCLC stage B patient TACE may repeat per standard care - EOS = End study treatment meet off-treatment study criterion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients must histopathological confirmation hepatocellular carcinoma ( HCC ) biliary tract carcinoma ( BTC ) Laboratory Pathology NCI prior enter study OR histopathological confirmation carcinoma set clinical radiological characteristic , together pathology , highly suggestive diagnosis HCC ( biliary tract carcinoma ) . Fibrolamellar variant also allow . The term BTC include intraor extrahepatic cholangiocarcinoma , gallbladder cancer ampullary cancer . 2 . Patients must disease amenable potentially curative resection , transplantation ablation . HCC patient must progress , intolerant , refuse prior sorafenib therapy . Patients BTC must receive , intolerant refuse least one line chemotherapy . 3 . Disease must technically amenable transhepatic arterial chemoembolization ( TACE ) ( HCC patient ) , radiofrequency ablation ( RFA ) , cryoablation . Each case discuss GI tumor board interventional radiology . Patients must evaluable disease . 4 . If liver cirrhosis present , patient must ChildPugh A/B7 classification 5 . Age &gt; 18 year 6 . ECOG performance status 02 7 . Patients must normal organ marrow function define : leukocyte great equal 3,000/mcL absolute neutrophil count great equal 1,000/mcL platelet great equal 60,000/mcL total bilirubin If cirrhosis present : Part Child Pugh requirement ; If cirrhosis : bilirubin le equal 2 xULN serum albumin If cirrhosis present : Part Child Pugh requirement ; If cirrhosis : albumin le equal 2.5g/dl patient eligible ALT AST 5 x ULN . creatinine &lt; 1.5x institution upper limit normal OR creatinine clearance great equal 45 mL/min/1.73 m^2 , calculate ; patient creatinine level institutional normal 8 . Patients must recover acute toxicity relate prior therapy , include surgery . Toxicity less equal grade 1 return baseline . 9 . Patients must invasive malignancy within past 5 year ( exception nonmelanoma skin cancer , noninvasive bladder cancer localize prostate cancer systemic therapy require ) . 10 . Patient must able understand willing sign write informed consent document . 11 . Evidence postmenopausal status negative urinary serum pregnancy test female premenopausal patient . Women consider postmenopausal amenorrheic 12 month without alternative medical cause . The follow agespecific requirement apply : Women &lt; 50 year age would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment luteinizing hormone folliclestimulating hormone level postmenopausal range institution underwent surgical sterilization ( bilateral oophorectomy hysterectomy ) . Women great equal 50 year age would consider postmenopausal amenorrheic 12 month follow cessation exogenous hormonal treatment , radiationinduced menopause last menses &gt; 1 year ago , chemotherapyinduced menopause last menses &gt; 1 year ago , underwent surgical sterilization ( bilateral oophorectomy , bilateral salpingectomy hysterectomy . Subject willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 12 . Body weight &gt; 30kg ( durvalumab + tremelimumab ) . EXCLUSION CRITERIA : 1 . Patients standard care chemotherapy , large field radiotherapy , major surgery must wait 2 week prior enter study . For recent experimental therapy 28 day period time must elapse treatment . 2 . Patients undergone prior liver transplantation ineligible . 3 . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 4 . Uncontrolled intercurrent illness include , limited , ongoing active systemic infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia ( exclude insignificant sinus bradycardia sinus tachycardia ) psychiatric illness/social situation would limit compliance study requirement . 5 . History chronic autoimmune disease ( e.g. , Addison disease , multiple sclerosis , Graves disease , Hashimoto thyroiditis , rheumatoid arthritis , hypophysitis , etc . ) symptomatic disease within 3 year randomization . Note : Active vitiligo history vitiligo basis exclusion . 6 . Dementia significantly alter mental status would prohibit understanding render Information Consent compliance requirement protocol . 7 . Diverticulitis either active history within past 2 year . Note diverticulosis permit . 8 . Active history inflammatory bowel disease ( colitis , Crohn ) , irritable bowel disease , celiac disease , serious , chronic , gastrointestinal condition associate diarrhea . Active history systemic lupus erythematosus Wegener granulomatosis . Currently receive immunosuppressive dos steroid immunosuppressive medication ( inhaled topical steroid permit ) 9 . History sarcoidosis syndrome 10 . Patients vaccinate live attenuate vaccine within 30 day start durvalumab tremelimumab treatment . 11 . Has know history Human Immunodeficiency Virus ( HIV ) . HIVpositive patient receive antiretroviral therapy exclude study due possibility pharmacokinetic interaction antiretroviral medication tremelimumab . HIV positive patient receive antiretroviral therapy exclude due possibility tremelimumab may worsen condition likelihood underlying condition may obscure attribution adverse event . 12 . History hypersensitivity reaction human mouse antibody product . 13 . Pregnancy breast feeding exclusion factor . The effect tremelimumab develop human fetus unknown . Enrolled patient must agree use adequate contraception prior study entry , duration study participation 6 month end treatment . Should woman become pregnant suspect pregnant partner participate study , inform treat physician immediately . 14 . Patients unhealed surgical wound 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 9, 2017</verification_date>
	<keyword>Liver Cancer</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>CTLA-4</keyword>
	<keyword>Ablative Therapy</keyword>
</DOC>